Skip to main content
455 search results for:

Albiglutide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2018 | News

    Albiglutide/canagliflozin

    Euglycemic diabetic ketoacidosis: case report
  2. Open Access 01-03-2018 | OriginalPaper

    Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide

    Albiglutide is a long-acting, glucagon-like peptide-1 receptor agonist (GLP-1RA) approved by the US Food and Drug Administration (FDA) in April 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes …

  3. 01-01-2017 | News

    Albiglutide

    Pancreatitis: case report
  4. 01-06-2014 | OriginalPaper

    Albiglutide: First Global Approval

    Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this …

  5. 01-04-2015 | OriginalPaper

    Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

    Albiglutide (Eperzan®, Tanzeum®), administered subcutaneously once weekly, is a glucagon-like peptide (GLP)-1 receptor agonist approved for the treatment of type 2 diabetes mellitus in several countries. Albiglutide has a longer half-life than …

  6. 01-07-2017 | ReviewPaper

    Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide

    Albiglutide is a long-acting, glucagon-like peptide-1 receptor agonist for subcutaneous administration with a recommended dose of 30–50 mg once weekly. The aim of this article is to outline the pharmacokinetic and pharmacodynamic properties of …

  7. Open Access 01-06-2014 | OriginalPaper

    Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

    Albiglutide is a novel glucagon-like peptide-1 (GLP-1) receptor agonist generated through genetic fusion of 2 tandem copies of modified human GLP-1 to human albumin. The GLP-1 sequence has been modified to confer resistance to dipeptidyl …

  8. Open Access 01-12-2014 | Erratum

    Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

    The authors of the above mentioned manuscript would like to make the following clarification. The associated ClinicalTrials.gov registration number for this GlaxoSmithKline trial “Albiglutide Thorough ECG Study in Healthy Volunteers” was …

  9. Open Access 01-02-2016 | OriginalPaper

    Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

    The medical management of patients with type 2 diabetes typically consists of diet and exercise, together with glucose-lowering medications having different mechanisms of action and possible side effects, including hypoglycaemia, weight gain …

  10. 01-12-2014 | OriginalPaper

    HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

    Type 2 diabetes is a progressive disease characterised by worsening beta cell function over time. Although patients respond well to lifestyle changes and initiation of monotherapy with oral antihyperglycaemic agents (usually metformin) to control …

  11. Open Access 25-01-2024 | Exenatide | ReviewPaper

    Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review

    Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used in the treatment of diabetes mellitus (DM) and obesity [ 1 , 2 ]. Beyond glucose control and weight reduction, GLP1RAs were shown to reduce cardiovascular morbidity and mortality …

  12. Open Access 01-12-2024 | Liraglutide | OriginalPaper

    Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

    Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are modified derivatives of glucagon-like peptide 1 (GLP-1) that simulate the regulatory effect of GLP-1 on blood glucose levels. The primary advantages of GLP-1RAs lie in glucose reduction …

  13. 05-05-2024 | Acute Pancreatitis | Online First

    The effect of incretin-based drugs on the riks of acute pancreatitis: a review

    In recent years, new hypoglycaemic drugs which affect the incretin system have gained increasing popularity in the treatment of type 2 diabetes mellitus (T2DM). Currently, two groups of incretin-based agents are available: glucagon-like peptide 1 …

  14. Open Access 01-12-2024 | Dapagliflozin | OriginalPaper

    Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

    Diabetes is a significant predisposing factor for microvascular and macrovascular complications with cardiovascular events 2–3 times more likely to occur in patients with diabetes than in those without diabetes [ 1 ]. Conventionally, the management …

  15. Open Access 12-03-2024 | Diabetic Nephropathy | Review

    Nephroprotective effects of incretin-based therapies

    Cardiovascular outcome trials indicate that incretin-based therapies have renal benefits beyond their glucose-lowering efficacy. But what is the evidence regarding the nephroprotective effects of these anti-diabetes compounds?

  16. 04-03-2024 | Bariatric Surgery | ReviewPaper

    Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review

    Addressing suboptimal weight loss post-bariatric surgery poses a challenge. While glucagon-like peptide 1 receptor agonists (GLP1-RA) show promise in managing obesity, their role as an adjuvant treatment after bariatric surgery remains uncertain.

  17. 14-05-2024 | Arterial Diseases | Online First

    Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment

    Polyvascular disease is the presence of atherosclerosis in at least two distinct vascular territories, most commonly resulting in coronary artery disease (CAD), cerebrovascular disease (CVD) and lower extremity peripheral artery disease (PAD) …

  18. Open Access 22-02-2024 | Type 2 Diabetes | OriginalPaper

    Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

    A precision medicine approach in type 2 diabetes would aim to target specific glucose-lowering therapies to individual patients most likely to benefit [ 1 ]. Current stratification in type 2 diabetes treatment guidelines involves preferential …

  19. Open Access 01-12-2021 | Stroke | OriginalPaper

    GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

    A significant reduction in the incidence of major cardiovascular events (MACE) has been observed in patients with type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 receptor agonists (GLP-1RA), suggesting the possibility of …

  20. 12-02-2024 | Diabetes Therapy | News | Article

    Pros and cons of GLP-1 receptor agonists for type 2 diabetes

    This was followed by mazdutide (2.09%), CagriSema (1.80%), orforglipron (1.49%), semaglutide (1.40%), retatrutide (1.32%), dulaglutide (1.09%), liraglutide (1.04%), polyethylene glycol (PEG)-loxenatide (1.04%), albiglutide (1.01%), PEGylated exenatide (0.97%), ITCA 650 pump delivery of exenatide (0.91%), exenatide (0.81%), efpeglenatide (0.74%), and lixisenatide (0.61%).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.